

Information about proposed Board of Directors Annual General Meeting 2023

Proposal for re-election of the current members of the Board of Directors:

Annette Clancy

Born 1954. BSc Hons Pharmacology from the University of Bath, United Kingdom. Board member since 2014.

Other appointments: Chair of the Board of Directors of Enyo SA. Operational Investor at Jeito Capital.

Previous appointments: Senior Advisor, Biopharmaceutical Team of Frazier Healthcare. Chair of the Board of Directors of Genable Therapeutics, Lysogene SA and Obseva SA. Board member of Silence Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management, Global Business Development at GlaxoSmithKline.

Shares: 3,414

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Bo Jesper Hansen

Born 1958. MD and PhD from the University of Copenhagen, Denmark. Board member since 2022.

Other appointments: Chair of the Board of Directors of Orphazyme A/S. Board member of Laborie Inc. and Reapplix A/S. Senior Advisor at EQT and Global Healthcare Advisor at Goldman Sachs, as well as Venture Partner at Wellington Partners, Senior Business Advisor at HBM Ventures and advisor at Aescap Venture Fund.

Previous appointments: CEO of Swedish Orphan International AB 1998–2010, co-founder of Swedish Orphan Biovitrum AB (publ), and executive chairman of the Board of Directors of Swedish Orphan Biovitrum AB (publ) 2010–2016. Board member of several listed companies and extensive experience from several executive positions within research and development in the international pharmaceutical industry.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Helena Saxon

Born 1970. Master of Science from Stockholm School of Economics, Sweden. Board member since 2011.

Other appointments: CFO at Investor AB. Board member of SEB and Stockholm School of Economics.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Shares: 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Staffan Schüberg

Born 1969. BA Hons Business Administration from the London Guildhall University, United Kingdom. Board member since 2020.

Other appointments: CEO and Board member of the ESTEVE Group. Board member of Dizlin Pharmaceuticals AB, Hangzhou Jiuyuan Gene Engineering Co. Ltd and Corporación Químico Farmacéutico Esteve S.A.

Previous appointments: More than 20 years of experience from Board and executive management roles, including several senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the U.S. operations and Global Chief Commercial Officer on Group level.

Shares: 4,500

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Filippa Stenberg

Born 1985. Master of Science in economics from Stockholm School of Economics, Sweden. Board member since 2021.

Other appointments: Managing Director at Investor AB.

Previous appointments: Head of Strategy at Atlas Antibodies. Analyst at Swedbank LC&I.

Shares: 500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Proposal for election of a new members of the Board of Directors:

Christophe Bourdon

Born 1970. MBA from International Institute for Management (IMD) Business School, Switzerland, and a BA from ISG Business School, France.

Other appointments: CEO of Leo Pharma A/S.

Previous appointments: CEO of Orphazyme A/S, Senior Vice President, General Manager, U.S Oncology Business and member of the Operating Team at Amgen Inc., Senior Vice President of Europe, Middle East, Africa and Canada at Alexion, as well as other key roles within the international pharmaceutical industry.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Anders Ullman

Born 1956. MD and PhD in Clinical Pharmacology from the University of Gothenburg, Sweden.

Other appointments: Board member of Verona Pharma plc.

Previous appointments: Head of Research & Development and Medical Affairs and Chief Medical Officer at Sobi. Board member of Sobi, NeuroSearch and PExA. Head of the COPD Centre at Sahlgrenska University Hospital. More than 20 years of experience from several executive positions within research and development in the international pharmaceutical industry, including Baxter Bioscience, Nycomed/Takeda, Biovitrum, Bayer Pharmaceuticals and AstraZeneca.

Shares: 3,000

Dependent in relation to the company and its management but independent in relation to the company's principal shareholders.